EPA formulation used in the EMT2 trial gets NICE approval for prevention of heart attacks and strokes
The formulation and dose of the omega-3 EPA (icosapent ethyl) that is being tested in the EMT2 trial was approved by NICE in July 2022...
Results 1 to 8 of 8
The formulation and dose of the omega-3 EPA (icosapent ethyl) that is being tested in the EMT2 trial was approved by NICE in July 2022...
Update JULY 2021 The EPA capsules used in the EMT2 trial have now received approval from the MHRA (the drugs approvals agency in the UK)...
Thanks to the commitment of trial participants and research staff, the EMT2 trial remains open and is recruiting well. Some hospitals have needed to stop...
Sept 2020 – The trial has re-started really well since July with 20 patients recruited by seven sites. We are seeking ethical approval to allow...
Thanks to hard work by the research sites and the Clinical Trials Unit, trial participant follow-up and capsule delivery via courier continued largely unaffected during...
May 2020 – the trial team is working with our hospital sites to re-start recruitment to the trial as soon as possible during the recovery...
Feb 2020 – working with teams at Cardiff, KCL and Oxford to open more sites in 2020 March 2020 – Our recruiting hospitals are working...
COVID-19 UPDATE – MESSAGE FOR PARTICIPANTS The Coronavirus epidemic (COVID-19) is causing disruption to all research trials taking place in the NHS, including EMT2. Research...